You are using an older browser version. Please use a supported version for the best MSN experience.

CHIASMA, INC.

NASDAQ: CHMA
4.67
-0.34
-6.90%

Sector

Healthcare

Industry

Pharmaceuticals

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Key People

David M. Stack

Independent Chairman of the Board

Mark J. Fitzpatrick

President

Drew Enamait

Vice President, Finance and Administration, Principal Accounting Officer

Roni Mamluk

Director

Todd Foley

Independent Director

  • Chiasma Inc

  • 140 Kendrick Street, Building C East

  • NEEDHAM, MA 02494

  • US.Map

  • Phone: +1 617 9285300

  • Fax: +1 339 2003009

  • chiasmapharma.com

Incorporated

2001

Employees

48

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 7/14/2020

    • KANNAN RAJ

    • Bought

    • 10,000

    • 4.20

    • 42,000.00

    • 2/20/2020

    • MAMLUK RONI PH.D.

    • NA

    • 82,186

    • 0.09

    • 7,396.74

    • 2/20/2020

    • MAMLUK RONI PH.D.

    • Sold

    • 82,186

    • 4.54

    • 373,124.44

    • 12/20/2019

    • MAMLUK RONI PH.D.

    • Sold

    • 61,139

    • 5.51

    • 336,875.89

    • 12/20/2019

    • MAMLUK RONI PH.D.

    • NA

    • 61,139

    • 0.09

    • 5,502.51

    • 10/16/2019

    • MAMLUK RONI PH.D.

    • Sold

    • 10,000

    • 4.94

    • 49,400.00

    • 10/16/2019

    • MAMLUK RONI PH.D.

    • NA

    • 10,000

    • 0.09

    • 900.00

    • 9/27/2019

    • LUDLAM WILLIAM

    • Bought

    • 5,050

    • 4.91

    • 24,783.38

    • 9/20/2019

    • MAMLUK RONI PH.D.

    • Sold

    • 50,000

    • 5.59

    • 279,500.00

    • 9/20/2019

    • MAMLUK RONI PH.D.

    • NA

    • 50,000

    • 0.09

    • 4,500.00

    • 8/19/2019

    • MINICK SCOTT

    • Bought

    • 9,818

    • 5.33

    • 52,329.94

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 7/14/2020

      • KANNAN RAJ

      • Bought

      • 10,000

      • 4.20

      • 42,000.00

      • 2/20/2020

      • MAMLUK RONI PH.D.

      • NA

      • 82,186

      • 0.09

      • 7,396.74

      • 2/20/2020

      • MAMLUK RONI PH.D.

      • Sold

      • 82,186

      • 4.54

      • 373,124.44

      • 12/20/2019

      • MAMLUK RONI PH.D.

      • Sold

      • 61,139

      • 5.51

      • 336,875.89

      • 12/20/2019

      • MAMLUK RONI PH.D.

      • NA

      • 61,139

      • 0.09

      • 5,502.51

      • 10/16/2019

      • MAMLUK RONI PH.D.

      • Sold

      • 10,000

      • 4.94

      • 49,400.00

      • 10/16/2019

      • MAMLUK RONI PH.D.

      • NA

      • 10,000

      • 0.09

      • 900.00

      • 9/27/2019

      • LUDLAM WILLIAM

      • Bought

      • 5,050

      • 4.91

      • 24,783.38

      • 9/20/2019

      • MAMLUK RONI PH.D.

      • Sold

      • 50,000

      • 5.59

      • 279,500.00

      • 9/20/2019

      • MAMLUK RONI PH.D.

      • NA

      • 50,000

      • 0.09

      • 4,500.00

      • 8/19/2019

      • MINICK SCOTT

      • Bought

      • 9,818

      • 5.33

      • 52,329.94

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon